MacroGenics, Inc. (MGNX) — Analysis Summary
MacroGenics, Inc. (MGNX) has a market cap of $236.96M with year-over-year revenue growth of -0.3%. Net margin stands at -49.9%. The stock trades at a P/E ratio of -16.2.
Key Takeaways
- Revenue changed -0.3% year-over-year
- Net margin of -49.9%
- P/E ratio of -16.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, MGNX posted revenue growth of -0.3% and trades at a P/E of -16.2.
MacroGenics, Inc. (MGNX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -2.7x — earnings do not cover interest payments
Operating margin at -29.5% — material operating losses
The latest filing shows negative free cash flow.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
293
Headquarters
Rockville, MD
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.